Porous PLGA microspheres for the inhalation delivery of icariin and miR－23b in the treatment of metastatic lung cancer

Abstract

Herein, porous poly(lactic-co-glycolic acid) (PLGA) microspheres were prepared to load icariin and miR-23b for the treatment of metastatic lung cancer. The microspheres exhibited desirable aerodynamic diameter, high drug loading and encapsulation efficiency, as well as a favorable drug release profile, which was beneficial for the deposition and exposure of drugs in the lung tissues. The release solution from microspheres exhibited a favorable anti-proliferative effect by inducting cell apoptosis and arresting the cell cycle at G1 phase, and meanwhile inhibited the migration and invasion of cancer cells. More importantly, the microspheres could be effectively inhaled and accumulated in the lung tissues to trigger the in situ apoptosis of tumor cells and suppress metastasis, using mice bearing melanoma-metastatic lung cancer as a model. Furthermore, inhalation of the microspheres showed favorable biocompatibility, barely causing tissue damage. Overall, porous PLGA microspheres provide a promising platform for the inhalable co-delivery of drugs and genes to obtain ideal therapeutic efficacy in lung cancer and other pulmonary diseases.

Keywords

PLGA microsphere / Icariin / miR-23b / Inhalation / Metastatic lung cancer

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Acknowledgments

The authors gratefully acknowledge the supports from the National Natural Science Foundation of China ( 32271319 and 32071267), the Science and Technology Department of Jilin Province (YDZJ202301ZYTS537 and 20240402035GH), the Development and Reform Commission of Jilin Province (2023C015), and the "Medicine + X" cross-innovation team of Bethune Medical Department of Jilin University "Leading the Charge with Open Competition" construction project (2022JBGS04).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajps.2024.101008. The figures and tables with " S " before the serial number are included in the Supplementary material.

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71( 3):209-49.

[2] Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet 2021; 398(10299):535-54.

[3] Li Q, Lin J, Hao G, Xie A, Liu S, Tang B. Nephrotoxicity of targeted therapy used to treat lung cancer. Front Immunol 2024; 15:1369118.

[4] Gao Q, Zhan Y, Sun L, Zhu W. Cancer stem cells and the tumor microenvironment in tumor drug resistance. Stem Cell Rev Rep 2023; 19(7):2141-54.

[5] Liu Y, Lin Y, Xiao H, Fu Z, Zhu X, Chen X, et al. mRNA-responsive two-in-one nanodrug for enhanced anti-tumor chemo-gene therapy. J Control Release 2024; 369:765-74.

[6] Alhakamy NA, Fahmy UA, Badr-Eldin SM, Ahmed OAA, Asfour HZ, Aldawsari HM, et al. Optimized icariin phytosomes exhibit enhanced cytotoxicity and apoptosis-inducing activities in ovarian cancer cells. Pharmaceutics 2020; 12(4):346.

[7] Zeng J, Sun P, Zhao Y, Fang X, Wu Z, Qi X. Bone mesenchymal stem cell-derived exosomes involved co-delivery and synergism effect with icariin via mussel-inspired multifunctional hydrogel for cartilage protection. Asian J Pharm Sci 2023; 18(3):100799.

[8] Liu Y, Yang H, Xiong J, Zhao J, Guo M, Chen J, et al. Icariin as an emerging candidate drug for anticancer treatment: current status and perspective. Biomed Pharmacother 2023; 157:113991.

[9] Tan H, Chan K, Pusparajah P, Saokaew S, Duangjai A, Lee L, et al. Anti-cancer properties of the naturally occurring aphrodisiacs: icariin and its derivatives. Front Pharmacol 2016; 7:191.

[10] Di S, Fan C, Yang Y, Jiang S, Liang M, Wu G, et al. Activation of endoplasmic reticulum stress is involved in the activity of icariin against human lung adenocarcinoma cells. Apoptosis 2015; 20(9):1229-41.

[11] Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017; 16(3):203-22.

[12] Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release 2013; 172(3):962-74.

[13] Shang R, Lee S, Senavirathne G, Lai EC. microRNAs in action: biogenesis, function and regulation. Nat Rev Genet 2023; 24(12):816-33.

[14] Guo Y, Wang N, Wu C, Li C, Chen R, Zhang Y, et al. The role of miR-23b in cancer and autoimmune disease. J Oncol 2021; 2021:6473038.

[15] Yan J, Jiang J, Meng X, Xiu Y, Zhong Z. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. J Exp Clin Cancer Res 2016; 35:31.

[16] Fulciniti M, Amodio N, Bandi R, Prabhala RH, Adamia S, Calimeri T, et al. MiR-23b plays a critical role as a tumor suppressor miRNA in multiple myeloma. Blood 2013; 122:122.

[17] Zhang H, Hao Y, Yang J, Zhou Y, Li J, Yin S, et al. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun 2011; 2:554.

[18] Hu Y, Yu Y, You S, Li K, Tong X, Chen S, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017; 16(1):174.

[19] Han H, Yang J, Wang Y, Chen W, Chen J, Yang Y, et al. Nucleobase-modified polyamidoamine-mediated miR-23b delivery to inhibit the proliferation and migration of lung cancer. Biomater Sci 2017; 5(11):2268-75.

[20] Kumbhar P, Manjappa A, Shah R, Jha NK, Singh SK, Dua K, et al. Inhalation delivery of repurposed drugs for lung cancer: approaches, benefits and challenges. J Control Release 2022; 341:1-15.

[21] Tang Y, Zhang L, Sun R, Luo B, Zhou Y, Zhang Y, et al. Pulmonary delivery of mucus-traversing PF127-modified silk fibroin nanoparticles loading with quercetin for lung cancer therapy. Asian J Pharm Sci 2023; 18(4):100833.

[22] Hittinger M, Juntke J, Kletting S, Schneider-Daum N, de Carvalho CS, Lehr CM. Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models. Adv Drug Deliv Rev 2015; 85:44-56.

[23] Mahar R, Chakraborty A, Nainwal N, Bahuguna R, Sajwan M, Jakhmola V. Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs. AAPS PharmSciTech 2023; 24(1):39.

[24] Arrighi A, Marquette S, Peerboom C, Denis L, Goole J, Amighi K. Development of PLGA microparticles with high immunoglobulin G-loaded levels and sustained-release properties obtained by spray-drying a water-in-oil emulsion. IntJ Pharm 2019; 566:291-8.

[25] Yang Y, Huang Z, Li J, Mo Z, Huang Y, Ma C, et al. PLGA porous microspheres dry powders for codelivery of afatinib-loaded solid lipid nanoparticles and paclitaxel: novel therapy for EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer. Adv Healthcare Mater 2019; 8(12):e1900965.

[26] Bitencourt CS, Silva LB, Pereira PA, Gelfuso GM, Faccioli LH. Microspheres prepared with different co-polymers of poly(lactic-glycolic acid) (PLGA) or with chitosan cause distinct effects on macrophages. Colloids Surf B: Biointerfaces 2015; 136:678-86.

[27] Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009; 30(10):1947-53.

[28] Shi X, Li C, Gao S, Zhang L, Han H, Zhang J, et al. Combination of doxorubicin-based chemotherapy and polyethylenimine/p53 gene therapy for the treatment of lung cancer using porous PLGA microparticles. Colloids Surf B: Biointerfaces 2014; 122:498-504.

[29] Wu D, Wang C, Yang J, Wang H, Han H, Zhang A, et al. Improving the intracellular drug concentration in lung cancer treatment through the codelivery of doxorubicin and miR-519c mediated by porous PLGA microparticle. Mol Pharm 2016; 13(11):3925-33.

[30] Li W, Chen S, Zhang L, Zhang Y, Yang X, Xie B, et al. Inhalable functional mixed-polymer microspheres to enhance doxorubicin release behavior for lung cancer treatment. Colloids Surf B: Biointerfaces 2020; 196:111350.

[31] Zhu L, Li M, Liu X, Jin Y. Drug-loaded PLGA electrospraying porous microspheres for the local therapy of primary lung cancer via pulmonary delivery. ACS Omega 2017; 2 (5):2273-9.

[32] Xiong B, Chen Y, Liu Y, Hu X, Han H, Li Q. Artesunate-loaded porous PLGA microsphere as a pulmonary delivery system for the treatment of non-small cell lung cancer. Colloids Surf B: Biointerfaces 2021; 206:111937.

[33] Bogdanov AA Jr, Gupta S, Koshkina N, Corr SJ, Zhang S, Curley SA, et al. Gold nanoparticles stabilized with MPEG-grafted poly(l-lysine): in vitro and in vivo evaluation of a potential theranostic agent. Bioconjugate Chem 2015; 26(1):39-50.

[34] Yang MY, Chan JG, Chan HK. Pulmonary drug delivery by powder aerosols. J Control Release 2014; 193:228-40.

[35] Cohausz O, Althaus FR. Role of PARP-1 and PARP-2 in the expression of apoptosis-regulating genes in HeLa cells. Cell Biol Toxicol 2009; 25(4):379-91.

[36] Martinez-Garcia D, Manero-Ruperez N, Quesada R, Korrodi-Gregorio L, Soto-Cerrato V. Therapeutic strategies involving survivin inhibition in cancer. Med Res Rev 2019; 39(3):887-909.

[37] Kim J, Shim MK, Yang S, Moon Y, Song S, Choi J, et al. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance. J Control Release 2021; 330:920-32.

[38] Mouw JK, Yui Y, Damiano L, Bainer RO, Lakins JN, Acerbi I, et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med 2014; 20(4):360-7.

[39] Sethia B, Kumar V, Jayasinghe TD, Dong Y, Ronning DR, Zhong HA, et al. Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma. J Control Release 2023; 354:80-90.

[40] Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011; 474(7350):230-4.

[41] Grunwald B, Vandooren J, Locatelli E, Fiten P, Opdenakker G, Proost P, et al. Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer. J Control Release 2016; 239:39-48.

[42] Liu L, Tao T, Liu S, Yang X, Chen X, Liang J, et al. An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness. Nat Commun 2021; 12(1):2693.

[43] Youngren-Ortiz SR, Gandhi NS, Espana-Serrano L, Chougule MB. Aerosol delivery of siRNA to the lungs. Part 1: rationale for gene delivery systems. Kona 2016; 33:63-85.

[44] Liang X, Wang Y, Shi H, Dong M, Han H, Li Q. Nucleolin-targeting AS 1411 aptamer-modified micelle for the co-delivery of doxorubicin and miR-519c to improve the therapeutic efficacy in hepatocellular carcinoma treatment. Int J Nanomed 2021; 16:2569-84.